An overview of the use of nanoparticles in vaccine development

Nanotechnology is revolutionizing vaccine development by addressing the limitations of traditional vaccines, including inefficacy against complex diseases like HIV, tuberculosis, and cancer. Nanoparticles, such as lipid nanoparticles, polymeric carriers, and virus-like particles (VLPs), mimic pathogens and enhance antigen delivery, triggering robust immune responses. These nano systems improve vaccine efficacy, stability, and safety by enabling targeted and controlled antigen release.

Notably, lipid nanoparticles have enabled mRNA vaccines for COVID-19, as demonstrated by the success of Moderna and Pfizer-BioNTech vaccines. Advanced delivery methods such as viral vectors, virosomes, and polymeric particles show promise for cancer immunotherapy and combating intracellular infections. Nanoparticle-based platforms also provide versatility across different administration routes, including oral, intranasal, and injectable formats, enhancing accessibility and compliance.

Despite promising advances, challenges like toxicity, regulatory standards, and large-scale manufacturing persist. Future prospects highlight nanotechnology's potential to develop next-generation vaccines capable of combating infectious diseases, cancer, and complex conditions effectively.